Logo

Focused on non-absorbed therapies
for patients with Chronic Kidney Disease

Overview

Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and increased mortality.

Tricida has successfully completed a pivotal Phase 3, double-blind, placebo-controlled trial of TRC101 in CKD patients with metabolic acidosis (TRCA-301) that evaluated the safety, tolerability and efficacy of TRC101 in subjects with CKD and metabolic acidosis. The results of the TRCA301 trial along with results from a successful double-blind, randomized, placebo-controlled Phase 1/2 trial and an ongoing safety extension trial, TRCA-301E, are intended to serve as the basis for the submission of a U.S. New Drug Application (NDA) for TRC101 under the Accelerated Approval Program of the U.S. Food and Drug Administration (FDA).

Tricida was founded in August of 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases.

Management Team

Gerrit Klaerner, PhD

Chief Executive Officer & President

Dr. Gerrit Klaerner, Ph.D., the Founder of the Company, has served as a member of our board of directors since July 2013 and as our Chief Executive Officer and President since August 2013. Dr. Klaerner was the Founder of Relypsa, Inc. and served as its President and as a member of its board of directors from October 2007 until June 2013. Dr. Klaerner co-founded Ilypsa, Inc. in 2003 and served as its Chief Business Officer and Senior Vice President from December 2006 until July 2007 and its Director of Technology Assessment and Business Development from January 2003 until December 2006. Dr. Klaerner served in Symyx Technologies, Inc. from October 1998 until January 2003 as Staff Scientist, Senior Staff Scientist and Director of Business Development. Dr. Klaerner received his Ph.D. in polymer and organic chemistry from the Max Planck Institute for Polymer Research in Mainz, Germany, his M.S. in Chemistry from the Philipps University of Marburg and completed post-doctoral research at Stanford University and the IBM Almaden Research Center.

Edward J. Hejlek, JD

General Counsel & Senior Vice President

Mr. Edward J. Hejlek, Esq., has served as our Senior Vice President and General Counsel since January 2016. Mr. Hejlek served as a Partner at Bryan Cave Leighton Paisner LLP from April 2008 until December 2015 and as an attorney at Senniger Powers LLP from 1983 until March 2008 (Partner from 1986 to March 2008). Mr. Hejlek also served as outside patent counsel to Ilypsa, Inc. from 2005 until March 2008 and as outside patent counsel to Relypsa, Inc. from 2007 to March 2008. He was an adjunct professor of law at the Saint Louis University School of Law from 1987 until 2012. He received a J.D. from University of Missouri-Columbia and a B.S. in Chemical Engineering from Washington University.

Claire Lockey

Chief Development Officer & Senior Vice President

Ms. Claire Lockey has served as our Senior Vice President and Chief Development Officer since November 2015. Ms. Lockey served as the Senior Vice President of Pharmaceutical Development and Regulatory Affairs at Relypsa, Inc. from February 2010 until November 2015.

Ms. Lockey served as Vice President of Regulatory Affairs at FibroGen, Inc. from July 2003 until January 2010 and has held similar executive-level positions at other biopharmaceutical companies including Titan Pharmaceuticals, Inc., Layton Bioscience, Inc., Connetics Corporation and Gore Hybrid Technologies, Inc., as well as a consulting position at Synergia LLC from 1985 until 1995. She received a B.A. in Biology from Boston University.

Geoffrey Parker

Chief Financial Officer & Senior Vice President

Mr. Geoffrey M. Parker has served as our Senior Vice President and Chief Financial Officer since April 2017. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, Inc. from September 2010 to May 2015. From 1997 to 2009, Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs. Mr. Parker has served as a member of the board of directors of Perrigo Company plc, Genomic Health, Inc., and ChemoCentryx, Inc. since November 2016, June 2016, and December 2009, respectively. Mr. Parker holds an AB degree in Economics and Engineering Sciences from Dartmouth College and an M.B.A. from Stanford University.

Dawn Parsell, PhD

Senior Vice President of Clinical Development

Dr. Dawn Parsell has served as our Senior Vice President of Clinical Development since August 2018.  Dr. Parsell has over 24 years of biotechnology and pharmaceutical industry experience, where she has been involved in the successful development and approval of nine FDA-approved drugs.  She has served as an independent regulatory consultant to the industry since 2001, providing strategic and tactical clinical and regulatory support to her clients, including assisting in the design and implementation of Tricida’s TRC101 development program since 2014.  From 1994 to 2001, Dr. Parsell worked at Connetics Corporation in discovery, clinical development and regulatory affairs positions, most recently as Director of Regulatory Affairs.  Dr. Parsell received a B.S. in Biochemistry and Genetics/Cell Biology with Distinction from the University of Minnesota, a Ph.D. in Biology from the Massachusetts Institute of Technology and completed a post-doctoral research fellowship at the Howard Hughes Medical Institute at The University of Chicago.

Wilhelm Stahl, PhD

Chief Technology Officer & Senior Vice President

Dr. Wilhelm Stahl, Ph.D., has served as our Senior Vice President and Chief Technology Officer since February 2017. Dr. Stahl served in several roles, including as Senior Vice President of Pharmaceutical Operations and as Chief Technology Officer, at Relypsa, Inc. from September 2011 until January 2017. Since January 2009, Dr. Stahl has been Managing Director of Rondaxe Deutschland OHG, a subsidiary of Rondaxe Enterprises, LLC, a consulting firm, providing consulting services and strategic advice on CMC aspects of drug development, supply chain management and strategic business support, where he was a Managing Partner from October 2009 to September 2011. From 2005 to 2008, Dr. Stahl was Head of the Pharma Custom Manufacturing business of Saltigo GmbH, a subsidiary of Lanxess AG. He received a Ph.D. in Chemistry from the Institute for Organic Chemistry and Biochemistry at the University of Bonn.

Board of Directors

Klaus Veitinger, MD, PhD

Chairman of the Board
Venture Partner, OrbiMed Advisors, LLC

Dr. Klaus R. Veitinger, M.D., Ph.D., M.B.A., has served as a member of our board of directors since February 2014 and as our chairman of the board since September 2015. Dr. Veitinger has served as a Venture Partner with OrbiMed Advisors LLC, an affiliate of one of our principal shareholders, since October 2007. Prior to OrbiMed Advisors, Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma, Inc. with responsibility for the U.S. and Asia businesses. Dr. Veitinger has served on the boards of public companies, including Intercept Pharmaceuticals, Inc. from August 2012 until July 2016 and Relypsa, Inc. from October 2010 until June 2015, and currently serves on the board of scPharmaceutical, Inc. since November 2017. Dr. Veitinger currently serves on the boards of directors of the following private companies: Neurogastrx, Inc. and Promentis Pharmaceuticals, Inc. For seven years he was a Director of PhRMA. Dr. Veitinger received his M.D. and his doctorate (Ph.D.) from the University of Heidelberg. He earned his M.B.A. at INSEAD in France.

Robert J. Alpern, MD

Dean and Ensign Professor
Yale School of Medicine

Dr. Robert J. Alpern, M.D., has served as a member of our board of directors since October 2013 and as chairman of our Scientific Advisory Board since October 2013. Dr. Alpern has served as the Ensign Professor of Medicine (Nephrology), Professor of Internal Medicine, and Dean of Yale School of Medicine since June 2004. He served as a Member of Scientific Advisory Board at Relypsa, Inc. from 2007 until 2014 and Ilypsa, Inc. from 2004 until 2007. From July 1998 until June 2004, Dr. Alpern was the Dean of The University of Texas Southwestern Medical School. Dr. Alpern has also served as a director of AbbVie Inc. since January 2013, Abbott Laboratories since October 2008 and has served on the board of trustees of Yale-New Haven Hospital since 2005. Dr. Alpern was on the leadership committee of the American Society of Nephrology and served as its president. Dr. Alpern has held or been awarded field-specific journal editorial board and fellowship positions, leadership positions in advisory councils and associations, and teaching awards. Dr. Alpern received his M.D. from the University of Chicago Pritzker School of Medicine and his B.A. in Chemistry from Northwestern University.

David Bonita, MD

Private Equity Partner, OrbiMed Advisors, LLC

Dr. David Bonita, M.D., has served as a member of our board of directors since January 2014. Since June 2013, Dr. Bonita has held the position of Private Equity Partner at OrbiMed Advisors LLC, an affiliate of one of our principal shareholders. From June 2004 to June 2013, Dr. Bonita held other positions at OrbiMed. Dr. Bonita has served on the boards of directors of Clementia Pharmaceuticals Inc. and View Ray Inc. since April 2013 and January 2008, respectively. Dr. Bonita also previously served on the boards of directors of Ambit Biosciences Corporation and Loxo Oncology, Inc. Dr. Bonita currently serves on the boards of directors of the following private companies: Acutus Medical Inc., Cryterion Medical Inc., Enobia Pharma Inc., Keystone Heart Ltd., Kyn Therapeutics Inc., Prelude Therapeutics Inc. and Si-Bone, Inc.; and has previously served on the board of directors of CardiAQ Valve Technologies, Inc. Dr. Bonita has also worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientific articles in peer- reviewed journals based on signal transduction research performed at the Harvard Medical School. He received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University.

Sandra I. Coufal, MD

Manager, Sibling Capital Ventures LLC

Dr. Sandra I. Coufal, M.D., has served as a member of our board of directors since July 2013 and as a member of our Scientific Advisory Board since August 2013. Dr. Coufal is a co-founder and has served as a co-manager of Sibling Capital Ventures LLC, an affiliate of one of our principal stockholders, since 2013. Dr. Coufal was a co-founder and a co-manager of Sibling Capital, LLC from 2012 to 2016. For the past 17 years, Dr. Coufal has been the Biomedical Advisor for the Genomics Institute of the Novartis Research Foundation. Dr. Coufal served as the Head of the Division of Internal Medicine at the Torrey Pines site of Scripps Clinic from 1997 until 1999, was a member of the board of directors of Scripps Green Hospital from 1997 until 1999. Dr. Coufal founded and served on Relypsa, Inc.’s Scientific Advisory Board since 2007 and was a co-founder of Ilypsa’s Scientific Advisory Board. Dr. Coufal has served on the boards of directors of BioAesthetics Corporation and SafetySpot Inc., since February 2016 and March 2017, respectively. Dr. Coufal served as Associate Faculty in the Division of Internal Medicine for the University of California San Diego. She completed an internship and residency in Internal Medicine at the University of Texas Southwestern Medical School at Dallas. Dr. Coufal received her M.D. from the University of Texas Southwestern Medical School at Dallas and received her B.S. in Science Preprofessional Studies from the University of Notre Dame and was designated a Notre Dame Scholar.

Ms. Kathryn Falberg has served as a member of our board of directors since May 2018. From March 2012 to March 2014, Ms. Falberg served as the Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc. From December 2009 to March 2012, Ms. Falberg held the position of Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc. From 2001 through 2009, Ms. Falberg worked with a number of smaller companies while serving as a corporate director and audit committee chair for several companies. From 1995 to 2001, Ms. Falberg served various roles at Amgen Inc., including as Senior Vice President, Finance and Strategy, and Chief Financial Officer, and as Vice President, Chief Accounting Officer, and as Vice President, Treasurer. Ms. Falberg currently serves on the boards of public companies, including Aimmune Therapeutics, Inc., Arcus Biosciences, Inc., Urogen Pharma Ltd., and The Trade Desk, Inc. Ms. Falberg previously served on the boards of directors of Axovant Sciences, Ltd., BioMarin Pharmaceutical Inc., Medivation Inc., Halozyme Therapeutics, Inc., aTyr Pharma, Inc., and multiple other companies. Ms. Falberg is an inactive certified public accountant. Ms. Falberg holds an M.B.A. in Finance and B.A. in Economics from the University of California, Los Angeles.

David Hirsch, MD, PhD

Managing Director, Longitude Capital

Dr. David Hirsch, M.D., Ph.D., has served as a member of our board of directors since July 2016. Since 2007, Dr. Hirsch has served as a Founder and Managing Director at Longitude Capital Management, an affiliate of one of our principal shareholders, where he focuses on investments in biotechnology. From 2005 to 2006, Dr. Hirsch was Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot Ventures, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Co. Dr. Hirsch currently serves on the boards of directors of the following public companies: Collegium Pharmaceutical, Inc., since 2012, and Molecular Templates, Inc., since 2017. Dr. Hirsch also serves on the boards of directors of the following private companies: Rapid Micro Biosystems, Inc., Velicept Therapeutics, Inc., and Zavante Therapeutics, Inc. Dr. Hirsch previously served on the boards of directors of Civitas Therapeutics, Inc. and Precision Therapeutics, Inc. Dr. Hirsch received his B.A. in Biology from The Johns Hopkins University, his M.D. from Harvard Medical School and his Ph.D. in Biology from the Massachusetts Institute of Technology.

Gerrit Klaerner, PhD

Chief Executive Officer & President,
Tricida, Inc.

Dr. Gerrit Klaerner, Ph.D., the Founder of the Company, has served as a member of our board of directors since July 2013 and as our Chief Executive Officer and President since August 2013. Dr. Klaerner was the Founder of Relypsa, Inc. and served as its President and as a member of its board of directors from October 2007 until June 2013. Dr. Klaerner co-founded Ilypsa, Inc. in 2003 and served as its Chief Business Officer and Senior Vice President from December 2006 until July 2007 and its Director of Technology Assessment and Business Development from January 2003 until December 2006. Dr. Klaerner served in Symyx Technologies, Inc. from October 1998 until January 2003 as Staff Scientist, Senior Staff Scientist and Director of Business Development. Dr. Klaerner received his Ph.D. in polymer and organic chemistry from the Max Planck Institute for Polymer Research in Mainz, Germany, his M.S. in Chemistry from the Philipps University of Marburg and completed post-doctoral research at Stanford University and the IBM Almaden Research Center.

Scientific and Clinical Advisory Board

Robert J. Alpern, MD

Chair
Dean and Ensign Professor
Yale School of Medicine

Dr. Robert J. Alpern, M.D., has served as a member of our board of directors since October 2013 and as chairman of our Scientific Advisory Board since October 2013. Dr. Alpern has served as the Ensign Professor of Medicine (Nephrology), Professor of Internal Medicine, and Dean of Yale School of Medicine since June 2004. He served as a Member of Scientific Advisory Board at Relypsa, Inc. from 2007 until 2014 and Ilypsa, Inc. from 2004 until 2007. From July 1998 until June 2004, Dr. Alpern was the Dean of The University of Texas Southwestern Medical School. Dr. Alpern has also served as a director of AbbVie Inc. since January 2013, Abbott Laboratories since October 2008 and has served on the board of trustees of Yale-New Haven Hospital since 2005. Dr. Alpern was on the leadership committee of the American Society of Nephrology and served as its president. Dr. Alpern has held or been awarded field-specific journal editorial board and fellowship positions, leadership positions in advisory councils and associations, and teaching awards. Dr. Alpern received his M.D. from the University of Chicago Pritzker School of Medicine and his B.A. in Chemistry from Northwestern University.

David A. Bushinsky, MD

Professor of Medicine and of Pharmacology and Physiology,
University of Rochester School of Medicine

Dr. David A. Bushinsky, M.D., is the John J. Kuiper Distinguished Professor of Medicine and of Pharmacology and Physiology at the University of Rochester School of Medicine. He is Chief of the Nephrology Division at the University of Rochester Medical Center and Associate Chair for Academic Affairs in the Department of Medicine. Dr Bushinsky has published several hundred peer-reviewed articles, invited reviews, chapters and editorials and has developed a strain of rats that exhibit genetic hypercalciuria, the most common metabolic abnormality in humans with nephrolithiasis, and spontaneously form kidney stones. The pathophysiolgy of the hypercalciuria closely parallels that of man and is thus a useful model to study stone formation in humans. His research has been consistently funded by grants from the National Institutes of Health for 3 decades and he has lectured throughout the world. Dr Bushinsky received his medical degree from Tufts University School of Medicine in Boston, Mass. He completed an internship and residency at Tufts New England Medical Center Hospital in Boston, Mass. He also completed a fellowship in clinical nephrology and a research fellowship in nephrology at Tufts New England Medical Center Hospital in Boston, Mass. Dr Bushinsky is a member of a number of organizations including the Association of American Physicians and the American Society for Clinical Investigation. He is married to Nancy Krieger, a pharmacologist and collaborator, and they have two children, Joshua and Seth.

Sandra I. Coufal, MD

Manager, Sibling Capital Ventures LLC

Dr. Sandra I. Coufal, M.D., has served as a member of our board of directors since July 2013 and as a member of our Scientific Advisory Board since August 2013. Dr. Coufal is a co-founder and has served as a co-manager of Sibling Capital Ventures LLC, an affiliate of one of our principal stockholders, since 2013. Dr. Coufal was a co-founder and a co-manager of Sibling Capital, LLC from 2012 to 2016. For the past 17 years, Dr. Coufal has been the Biomedical Advisor for the Genomics Institute of the Novartis Research Foundation. Dr. Coufal served as the Head of the Division of Internal Medicine at the Torrey Pines site of Scripps Clinic from 1997 until 1999, was a member of the board of directors of Scripps Green Hospital from 1997 until 1999. Dr. Coufal founded and served on Relypsa, Inc.’s Scientific Advisory Board since 2007 and was a co-founder of Ilypsa’s Scientific Advisory Board. Dr. Coufal has served on the boards of directors of BioAesthetics Corporation and SafetySpot Inc., since February 2016 and March 2017, respectively. Dr. Coufal served as Associate Faculty in the Division of Internal Medicine for the University of California San Diego. She completed an internship and residency in Internal Medicine at the University of Texas Southwestern Medical School at Dallas. Dr. Coufal received her M.D. from the University of Texas Southwestern Medical School at Dallas and received her B.S. in Science Preprofessional Studies from the University of Notre Dame and was designated a Notre Dame Scholar.

John S. Fordtran, MD

Director of Gastrointestinal Physiology,
Baylor University Medical Center

Dr. John Fordtran, M.D., is Director of Gastrointestinal Physiology, Baylor University Medical Center, Dallas, Texas. Dr. Fordtran received his medical degree from Tulane Medical School, New Orleans. He is the former Chief of Internal Medicine, Baylor University Medical Center, President of the Baylor Research Institute and co-editor, Gastrointestinal Disease – Pathophysiology, Diagnosis, Management. Edited by Marvin H. Sleisenger and John S. Fordtran, W. B. Saunders Company (Philadelphia). He was also the associate editor of the Journal of Clinical Investigation (1972-1977) and editor of Gastroenterology (1977-1981). Dr. Fordtran has published over 180 peer-reviewed articles with specific interest in the physiology and pathophysiology of the absorption and secretion of water and solutes in the human gastrointestinal tract. He received numerous honors, among them the Janssen Award in Gastroenterology for Lifetime Achievement in Digestive Sciences and he was the first Dr. Joseph B. Kirsner Visiting Scholar at The University of Chicago, in recognition of Outstanding Scholarship and Leadership in Gastroenterology.

Craig J. Hawker, PhD

Director, Materials Research Laboratory;
Professor of Chemistry, Biochemistry and Materials,
University of California, Santa Barbara

Dr. Craig Hawker, Ph.D., is currently Director of the Materials Research Laboratory and a Professor of Chemistry, Biochemistry and Materials at the University of California, Santa Barbara. From 1993-2004 he was a Research Staff Member and an investigator in the NSF Center for Polymer Interfaces and Macromolecular Assemblies at the IBM Almaden Research Center. He received a B.Sc. (Hons) degree and University Medal in Chemistry from the University of Queensland in 1984 and a Ph.D. in bioorganic chemistry from the University of Cambridge in 1988 under the supervision of Prof. Sir Alan Battersby. Jumping into the world of polymer chemistry, he undertook a post-doctoral fellowship with Prof. Jean Fréchet at Cornell University from 1988 to 1990 and then returned to the University of Queensland as a Queen Elizabeth II Fellow from 1991 to 1993. He has been honored by numerous awards and is Editor of the Journal of Polymer Science, Polymer Chemistry.

Thomas H. Hostetter, MD

Professor of Medicine and Vice Chairman for Research,
Case Western Reserve University, School of Medicine

Dr. Thomas H. Hostetter, M.D., is Professor of Medicine and Vice Chairman for Research in the Department of Medicine at Case Western Reserve University, School of Medicine. He was previously Abraham Levitt Professor of Medicine and Director of the Nephrology Division at Albert Einstein College of Medicine in New York for 6 years. For nearly 5 years before that he was a Senior Scientific Advisor and founding Director of the National Kidney Disease Education Program at the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Prior to that he had been Professor of Medicine at the University of Minnesota, where he was also Director of the Renal Division in the Department of Medicine for 15 years. He received his bachelor’s degree in chemistry from Yale University. After graduating from Baylor College of Medicine, Dr. Hostetter served his internship at Baylor and the remainder of his residency at the Peter Bent Brigham Hospital. Following his nephrology fellowship at the Brigham, he was a member of the faculty of Harvard Medical School until moving to Minnesota in 1982. Dr. Hostetter’s major research interests are the mechanisms of progressive renal disease and uremia. He was president of the American Society of Nephrology from 1999 to 2000 and was later chair of its Public Policy Board for 5 years. He has served on several editorial boards, study sections of the NIH, the Nephrology board of the American Board of Internal Medicine, the councils of the American and International Societies of Nephrology and as a consultant to industry.

Vandana Mathur, MD, FASN

President,
Mathur Consulting

Dr. Vandana Mathur, M.D., FASN, is a nephrologist, clinical trialist, and a Fellow of the American Society of Nephrology. She was faculty on the Renal Transplant Service at the University of California San Francisco (UCSF) and a consultant for the UCSF Drug Studies Unit. Since 2000, Dr. Mathur has served as the president of a clinical drug development and medical marketing support consulting company specializing in the design, conduct, and regulatory submission of clinical trials for pharmaceutical companies. Her clinical development therapeutic area work has spanned multiple therapeutic areas including nephrology, cardiology, hematology, oncology, and pain as well as drug-device combination products. Prior to founding Mathur Consulting, Dr. Mathur worked for several Silicon Valley biotechnology companies, ultimately in the role of Vice-President of Clinical Development and Medical Affairs. In these various roles, she has been integrally involved in the filing of 12 consecutive, successful New Drug Applications. She has lectured extensively in the United States and abroad, is the recipient of multiple teaching awards, has published several dozen peer-reviewed publications and book chapters, and is an inventor on eight patents. Dr. Mathur graduated from the University of Pennsylvania in Philadelphia with Honors in Biology and from the University of Pennsylvania School of Medicine. She then completed a nephrology and transplantation fellowship and the Clinical Scholars Program in epidemiology and biostatistics at the UCSF. She maintains an active clinical practice in San Francisco.

Bertram Pitt, MD

Professor of Medicine Emeritus,
University of Michigan School of Medicine

Dr. Bertram Pitt, M.D., is Professor of Medicine Emeritus at the University of Michigan School of Medicine. Dr. Pitt received his MD degree in 1959 from the University of Basel, Switzerland. He then did a fellowship in cardiology at the Johns Hopkins University School of Medicine, where he remained on the faculty until leaving to direct the division of cardiology at the University of Michigan School of Medicine in 1977. Dr. Pitt has chaired or co-chaired a number of clinical trials in cardiology including SOLVD; ELITE I and II; Prevent; Rales and Ephesus and has over 500 articles in peer reviewed journals. Dr. Pitt has been a member of a numerous medical journal editorial boards and medical organizations, and has served as an advisor to the clinical trials branch of the NHLBI and a member of the FDA cardio-renal advisory board. He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association and has been elected to the Society of Scholars of the Johns Hopkins University.

Navdeep Tangri, MD, PhD, FRCP(C)

Associate Professor of Medicine
Department of Medicine and Community Health Sciences
Scientific Director, Chronic Disease Innovation Center
University of Manitoba

Dr. Navdeep Tangri, M.D., Ph.D., F.R.C.P.(C), is an attending physician and Associate Professor in the Division of Nephrology, Department of Medicine and the Department of Community Health Sciences at the University of Manitoba. Dr. Tangri’s research program is clinical and translational and focused on improving clinical decision making for patients with advanced chronic kidney disease. He developed and validated the Kidney Failure Risk Equation to predict the need for dialysis in patients with CKD and is presently engaged in multiple validation and implementation exercises to increase the uptake of the KFRE. In addition, Dr. Tangri is conducting a large prospective study on frailty, physical and cognitive function in advanced CKD, as well as comparative effectiveness studies on the safety and effectiveness of medical therapies in this population. He has published over 170 manuscripts and presented at multiple national and international scientific meetings. He is a member of the editorial board of the American Journal of Kidney Disease, Clinical Journal of the American Society of Nephrology, Canadian Journal of Kidney Health and Disease and is Section Editor for the Epidemiology and Prevention Issue of Current Opinion in Nephrology and Hypertension. He has received the CIHR New Investigator Award and a CIHR foundation award for his work on CKD progression.